This complaint was first surfaced by Law.com Radar, ALM's source for immediate alerting on just-filed cases in state and federal courts. Law.com Radar now offers state court coverage nationwide. Sign ...

Novartis faces short-term challenges with patent expirations but shows long-term growth potential, making the stock a buy ...

The U.S. Court of Appeals for the Federal Circuit (CAFC) today issued a precedential decision reversing a district court’s ...

The Federal Circuit reversed a Delaware district court’s 2023 ruling axing a Novartis Pharmaceuticals Corp. patent covering ...

Nuvalent's NVL-655 and Zidesamtinib show strong potential as first-line therapies for NSCLC. Click here to find out why I ...

Two factors often determine stock prices in the long run: earnings and interest rates. Investors can't control the latter, but they can focus on a company's earnings results every quarter. Life and ...

USA-based Light Horse Therapeutics has been established as a new small molecule therapeutics developer, with a $62 million ...

Marea’s Phase IIa study enrolled patients with hypertriglyceridemia—too much fat in the blood. The latest results showed the ...

Royalty Pharma said on Friday it would pay about $1.1 billion to acquire RP Management, an organization that manages the healthcare firm's operations, as it seeks to simplify its corporate structure.

Windward Bio has landed with a flurry of announcements, circling in a $200 million series A and offering up to $970 million ...

Can science prevail against this more turbulent backdrop of the Trump administration? Yahoo Finance executive editor Brian ...

Previously at MeiraGTx, GSK and Novartis, Dr. Leighton will help Chemify scale the company’s operational capacity to meet ...